TY - JOUR
T1 - Aztreonam therapy in neutropenic patients with cancer
AU - Jones, Paula G.
AU - Rolston, Kenneth V.I.
AU - Fainstein, Victor
AU - Elting, Linda
AU - Walters, Ronald S.
AU - Bodey, Gerald P.
PY - 1986/8
Y1 - 1986/8
N2 - Combinations of aztreonam/vancomycin, aztreonam/vancomycin/ amikacin, and moxalactam/ticarcillin were compared in a prospective randomized trial as empiric therapy for febrile neutropenic cancer patients. Vancomycin was added to aztreonam to provide coverage against gram-positive organisms. Of 535 febrile episodes included in the study, 455 were evaluable. The aztreonam/vancomycin and aztreonam/vancomycin/amikacin combinations were both more effective than the moxalactam/ticarcillin combination in a total of 244 episodes of documented infection. The difference was due to the fact that both aztreoman-containing combinations were more effective than the moxalactam/ticarcillin combination in documented gram-positive infections. The three regimens were equally effective in 67 documented infections due to a single gram-negative bacterial species. (The response rates were 87, 86 and 94 percent for the aztreonam/ vancomycin, aztreonam/vancomycin/amikacin, and moxalactam/ticarcillin combinations, respectively.) Aztreonam was effective as the single active antibiotic in the treatment of gram-negative infections in neutropenic patients; however, it must be used in combination with another antibiotic to provide gram-positive coverage.
AB - Combinations of aztreonam/vancomycin, aztreonam/vancomycin/ amikacin, and moxalactam/ticarcillin were compared in a prospective randomized trial as empiric therapy for febrile neutropenic cancer patients. Vancomycin was added to aztreonam to provide coverage against gram-positive organisms. Of 535 febrile episodes included in the study, 455 were evaluable. The aztreonam/vancomycin and aztreonam/vancomycin/amikacin combinations were both more effective than the moxalactam/ticarcillin combination in a total of 244 episodes of documented infection. The difference was due to the fact that both aztreoman-containing combinations were more effective than the moxalactam/ticarcillin combination in documented gram-positive infections. The three regimens were equally effective in 67 documented infections due to a single gram-negative bacterial species. (The response rates were 87, 86 and 94 percent for the aztreonam/ vancomycin, aztreonam/vancomycin/amikacin, and moxalactam/ticarcillin combinations, respectively.) Aztreonam was effective as the single active antibiotic in the treatment of gram-negative infections in neutropenic patients; however, it must be used in combination with another antibiotic to provide gram-positive coverage.
UR - http://www.scopus.com/inward/record.url?scp=0022544693&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022544693&partnerID=8YFLogxK
U2 - 10.1016/0002-9343(86)90258-5
DO - 10.1016/0002-9343(86)90258-5
M3 - Article
C2 - 3526885
AN - SCOPUS:0022544693
SN - 0002-9343
VL - 81
SP - 243
EP - 248
JO - The American journal of medicine
JF - The American journal of medicine
IS - 2
ER -